Haixi Pharmaceutical (02637) has a total market value of HK$2,013 billion. Shareholders of the company deposited 9.873 million shares into CMB International Securities

Zhitongcaijing · 2d ago

The Zhitong Finance App learned that according to the latest data from the Hong Kong Stock Exchange, Haixi New Pharmaceutical (02637) changed positions on July 9, with a total market value of HK$2,013 billion, accounting for 12.60%. The company's shareholders deposited 9.873 million shares into CMB International Securities, increasing their shareholding ratio by 12.55%.

Haixi New Pharmaceutical announced that the C019199 tablets independently developed by the company have officially launched a phase III clinical trial (CTR20261818) for osteosarcoma that has failed at least second-line treatment. The relevant information has been published by the China National Drug Administration (NMPA) Drug Evaluation Center (CDE) drug clinical trial registration and information disclosure platform.